Celaid Therapeutics Completes Second Close of Series B Financing Round

CLD-001Positive

AI Analysis

Summary

Celaid Therapeutics completed the second close of its Series B financing round with participation from Shionogi and Teikoku Ventures to accelerate U.S. clinical trial preparations for CLD-001.

Outcome Details

Second close of Series B financing round completed

Importance:6/10

Sentiment:

0.60

financingSeries Bclinical trialCLD-001

Related Companies

$SGIOY

Read the original article

Published by PR Newswire Pharma on October 5, 2026 1:30 AM

Read Original